We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Tysabri Closer to Returning to Market Following Advisory Panel Recommendation
Tysabri Closer to Returning to Market Following Advisory Panel Recommendation
March 10, 2006
Biogen Idec and Elan’s multiple sclerosis (MS) drug Tysabri is one step closer to returning to the market after an FDA advisory panel recommended doing so under certain conditions.